logo-loader
viewBarsele Minerals Corp.

Barsele Minerals files previously announced technical report on Swedish project

InnovExplo concluded that there are several opportunities to add additional mineral resources by drilling the depth extensions of the oreshoot that originates in the resource area and the lateral extensions of the currently identified zones

The Barsele project in northern Sweden
The exploration program at Barsele is being operated by joint venture partner Agnico Eagle

Barsele Minerals Corp (CVE:BME) has filed the technical report in support of the independent updated mineral resource estimate presented in February.

The report pertains to the project at Vasterbottens Lan, northern Sweden.

READ Barsele Minerals pleased with progress at Swedish project as it unveils new resource estimate​

The basis for the 10 million to 15 million tonnage and the 2.5 grams per tonne (g/t) to 3.0 g/t gold grade range for the target includes the following comments from the report.

"Three mineralized zones have been identified on the property and are the subject of the mineral resource estimate in the NI 43-101 technical report. Collectively, these three zones are open vertically and have a sufficient footprint to potentially host additional mineralization.

"It is assumed that these mineralized zones will have similar width and continuity in their vertical extensions. This is supported by the fact that the bulk of the current mineral resource estimate is found within the first 600 metres and some drill holes encountered mineralization down to 850 metres. Drilling the gaps between some of the zones is also considered in this assumption.

"The grade range is considered reasonable based on the current mineral resource estimate."

Quick facts: Barsele Minerals Corp.

Price: 0.42 CAD

TSX-V:BME
Market: TSX-V
Market Cap: $51.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

10 hours, 33 minutes ago

2 min read